To this end, we analyzed numerous publicly available datasets, ranging from immunosuppressed states (as negative control), infectious diseases (both viral and bacterial; as positive control), and autoimmune diseases (Fig. 3d), and assessed the ability of ViP/sViP signatures to classify control and diseased samples in each dataset. This evidence concerns the gene VIP and infectious disease.